ARGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
ARGENX SE
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 19, 2026
$825.61+6.47 (+0.79%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 42.2
- Dividend yield
- –
Share price
−$18.05 (−2.14%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- 42.2
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- $1.29B
- EPS, diluted
- $19.57
- Free cash flow
- $679.03M
Eleven years at a glance
Fiscal years 2015 to 2025, USD
Revenue
–
Gross profit
–
Operating income
$1.05B
Net income
$1.29B+55.1% YoY
EPS, diluted
$19.57+53.1% YoY
Free cash flow
$679.03M
Reported period